Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biotech Bread Winners of 2002

This article was originally published in Start Up

Executive Summary

Private financings were down in 2002 across all sectors -- just 353 were completed, versus 438 in 2001 and 504 in 2002. The biggest stacks of money went to start-ups with the potential to bring numerous products to market, particularly to spin-offs. Quite a few of the big financings went to private companies that almost certainly would have launched a public stock offering if times were better. Start-ups lacking superstar pedigrees are now competing against public firms whose stock prices have fallen, as the dismal market encourages investors to expend their efforts on organizations and products that already exist. Cyclical as markets may be, this trend isn't likely to evaporate even if the financing climate warms up in 2002.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel